Skip to main content
. 2025 Sep 16;51:101225. doi: 10.1016/j.lana.2025.101225

Table 2.

HPV vaccine doses received by case-control status.

Characteristic Total, N = 524 Cases, N = 132 Controls, N = 392
≥1 dose any time before focal time
 No 383/524 (73·1%) 105/132 (79·5%) 278/392 (70·9%)
 Yes 141/524 (26·9%) 27/132 (20·5%) 114/392 (29·1%)
Time between 1st HPV dose and focal time
 Median (IQR), months 57·0 (40·0–88·0) 49·0 (27·0–83·0) 57·5 (43·0–89·0)
≥1 dose ≥2 years before focal time
 No 396/524 (75·6%) 109/132 (82·6%) 287/392 (73·2%)
 Yes 128/524 (24·4%) 23/132 (17·4%) 105/392 (26·8%)
Total number of doses before focal time
 1 dose 13/128 (10·2%) 0/23 (0·0%) 13/105 (12·4%)
 2 doses 13/128 (10·2%) 3/23 (13·0%) 10/105 (9·5%)
 ≥3 doses 102/128 (79·7%) 20/23 (87·0%) 82/105 (78·1%)
Age of first dose
 ≤18 years 34/128 (26·6%) 4/23 (17·4%) 30/105 (28·6%)
 >18–22 years 55/128 (43·0%) 13/23 (56·5%) 42/105 (40·0%)
 >22 years 39/128 (30·5%) 6/23 (26·1%) 33/105 (31·4%)
 Median age (IQR), years 21·0 (18·0–23·0) 21·0 (19·0–23·0) 21·0 (18·0–23·0)

Data are presented as median interquartile range (IQR) for continuous measures, and n/total (%) for categorical measures.